Epigenetics and the RVX IP and portfolio could be a game changer for many years of development and opportunity for the right BP, given previous studies, ad hoc data, and safety. And the BTD and better BoM2 details make APB a near term opportunity, in the bigger picture. Hopefully a BP sees the opportunity and takes us out at some point soon, but I get the impression that DM and this BoD seem to want to go it alone toward larger opportunities, compared to previous low ball offers - perhaps?

If anyone wants a six-figure+ block of shares for $5 let me know haha ... jk I am in till the end, one way or the other. And even still tempted to buy more at this current level.